4.6 Review

C9orf72-mediated ALS and FTD: multiple pathways to disease

Journal

NATURE REVIEWS NEUROLOGY
Volume 14, Issue 9, Pages 544-558

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41582-018-0047-2

Keywords

-

Funding

  1. Wellcome Trust [107196/Z/14/Z]
  2. Motor Neuron Disease Association
  3. Alzheimer's Research UK
  4. European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme [648716 - C9ND]
  5. UK Dementia Research Institute
  6. MRC [UKDRI-1006] Funding Source: UKRI

Ask authors/readers for more resources

The discovery that repeat expansions in the C9orf72 gene are a frequent cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) has revolutionized our understanding of these diseases. Substantial headway has been made in characterizing C9orf72-mediated disease and unravelling its underlying aetiopathogenesis. Three main disease mechanisms have been proposed: loss of function of the C9orf72 protein and toxic gain of function from C9orf72 repeat RNA or from dipeptide repeat proteins produced by repeat-associated non-ATG translation. Several downstream processes across a range of cellular functions have also been implicated. In this article, we review the pathological and mechanistic features of C9orf72-associated FTD and ALS (collectively termed C9FTD/ALS), the model systems used to study these conditions, and the probable initiators of downstream disease mechanisms. We suggest that a combination of upstream mechanisms involving both loss and gain of function and downstream cellular pathways involving both cell-autonomous and non-cell-autonomous effects contributes to disease progression.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available